iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors March 18, 2025
BioCity Biopharmaceutics Announces Clinical Collaboration to Evaluate BC3195 + KEYTRUDA combination in Patients with Locally Advanced or Metastatic Solid Tumors March 18, 2025
Pierre Fabre Laboratories and RedRidge Bio Announce Drug Discovery and Co-development Partnership March 12, 2025
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers March 4, 2025
Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm’s Innovative T Cell Therapies for Solid Cancers March 4, 2025
Additional Positive Data from Ph 2 Trial of NP-G2-044 in Patients with Advanced and Metastatic Solid Tumors Presented March 4, 2025
Positive Clinical Data Demonstrating Survival and Clinical Responses with triple combination of Versamune® HPV, PDS01ADC and a PD-L1 inhibitor in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology March 4, 2025
All clinical studies evaluating TIDAL-01 to discontinue and further development of the program halted February 11, 2025
FDA feedback provided on potential ELI-002 Ph 3 study design, including dose, schedule, patient population and primary endpoint analysis January 28, 2025
ArsenalBio and BMS Achieve Milestone for AB-4000 Series to Advance Next-Gen T Cell Therapies for Solid Tumors January 21, 2025
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Precision Cell Therapies Using Proprietary Tmod Technology Platform January 21, 2025
Interim Data Demonstrating Safety & Confirmed Clinical Responses of ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Ph 1b/2 Trial Announced January 11, 2025